REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. Show more

9804 Medical Center Drive, Rockville, MD, 20850, United States

https://www.regenxbio.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

401.9M

52 Wk Range

$5.04 - $16.19

Previous Close

$7.94

Open

$7.85

Volume

562,257

Day Range

$7.85 - $8.29

Enterprise Value

288.8M

Cash

274.2M

Avg Qtr Burn

-55.96M

Insider Ownership

8.16%

Institutional Own.

83.38%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Clemidsogene lanparvovec (RGX-121) Details Mucopolysaccharidosis II (MPS II), aka Hunter syndrome	BLA FDA meeting	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABBV-RGX-314 (Subretinal Delivery) Details Wet age-related macular degeneration (wet AMD)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RGX-202 Details Duchenne muscular dystrophy	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Surabgene lomparvovec (sura-vec, ABBV-RGX-314) (Suprachoroidal Delivery) Details Diabetic retinopathy (DR)	Phase 2/3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABBV-RGX-314 (Suprachoroidal Delivery) Details Wet age-related macular degeneration	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RGX-381 Details Central nervous system illness	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RGX-111 Details Mucopolysaccharidoses, Rare genetic disease, Genetic disorder, Rare diseases, Mucopolysaccharidosis Type 1	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RGX-181 Details Central nervous system illness, Batten Disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.